Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 5547 | 29.33 |
09:34 ET | 864 | 29.395 |
09:41 ET | 200 | 29.405 |
09:43 ET | 2297 | 29.39 |
09:45 ET | 400 | 29.35 |
09:48 ET | 100 | 29.37 |
09:50 ET | 100 | 29.36 |
09:54 ET | 1335 | 29.22 |
09:56 ET | 1255 | 29.345 |
09:57 ET | 954 | 29.32 |
09:59 ET | 100 | 29.36 |
10:01 ET | 2718 | 29.51 |
10:03 ET | 659 | 29.42 |
10:06 ET | 300 | 29.42 |
10:08 ET | 500 | 29.31 |
10:10 ET | 236 | 29.33 |
10:12 ET | 1577 | 29.42 |
10:14 ET | 100 | 29.39 |
10:15 ET | 103 | 29.39 |
10:17 ET | 400 | 29.39 |
10:19 ET | 200 | 29.32 |
10:21 ET | 300 | 29.38 |
10:24 ET | 200 | 29.42 |
10:26 ET | 100 | 29.43 |
10:28 ET | 300 | 29.46 |
10:30 ET | 300 | 29.47 |
10:32 ET | 3640 | 29.46 |
10:33 ET | 200 | 29.44 |
10:37 ET | 1000 | 29.505 |
10:39 ET | 1917 | 29.48 |
10:42 ET | 200 | 29.51 |
10:44 ET | 2200 | 29.51 |
10:46 ET | 400 | 29.52 |
10:48 ET | 1100 | 29.52 |
10:50 ET | 409 | 29.57 |
10:51 ET | 784 | 29.5 |
10:53 ET | 300 | 29.51 |
10:55 ET | 100 | 29.52 |
10:57 ET | 200 | 29.43 |
11:00 ET | 300 | 29.49 |
11:02 ET | 1200 | 29.575 |
11:08 ET | 1238 | 29.5867 |
11:09 ET | 200 | 29.6 |
11:11 ET | 300 | 29.57 |
11:13 ET | 300 | 29.57 |
11:15 ET | 100 | 29.57 |
11:18 ET | 600 | 29.59 |
11:20 ET | 100 | 29.62 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 4.2B | -10.4x | --- |
CRISPR Therapeutics AG | 4.0B | -14.8x | --- |
Axsome Therapeutics Inc | 4.3B | -13.9x | --- |
ADMA Biologics Inc | 4.5B | 138.2x | --- |
Apellis Pharmaceuticals Inc | 3.6B | -10.9x | --- |
TG Therapeutics Inc | 3.6B | 39.9x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 143.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-2.85 |
Book Value | $7.45 |
P/E Ratio | -10.4x |
Price/Sales (TTM) | 3,307.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,938.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.